Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Barclays analyst Matt Miksic maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of $158.00.

Shares of Abbott Laboratories advanced 3.74% to $131.35 Thursday, on what proved to be an all-around poor trading session for ...

In a report released on March 27, Josh Jennings from TD Cowen reiterated a Buy rating on Abbott Laboratories (ABT – Research Report), with a ...

In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other best S&P 500 stocks for dividend growth. Dividend stocks have been attracting increasing ...

We recently published a list of Diamond Hill Capital Stock Portfolio: Top 10 Stock Picks. In this article, we are going to ...

Abbott Laboratories closed 10.57% short of its 52-week high of $141.23, which the company reached on March 4th.

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...

Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...

Abbott Laboratories closed 11.07% short of its 52-week high of $141.23, which the company achieved on March 4th.